USP7 Is a Tumor-Specific WNT Activator for APC -Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination
Author(s) -
Laura Novellasdemunt,
Valentina Foglizzo,
Laura Gómez-Cuadrado,
Pedro Antas,
Anna Kucharska,
Vesela Encheva,
Ambrosius P. Snijders,
Vivian Li
Publication year - 2017
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2017.09.072
Subject(s) - adenomatous polyposis coli , wnt signaling pathway , catenin , cancer research , colorectal cancer , beta catenin , biology , chemistry , cancer , microbiology and biotechnology , genetics , signal transduction
The tumor suppressor gene adenomatous polyposis coli (APC) is mutated in most colorectal cancers (CRCs), resulting in constitutive Wnt activation. To understand the Wnt-activating mechanism of the APC mutation, we applied CRISPR/Cas9 technology to engineer various APC-truncated isogenic lines. We find that the β-catenin inhibitory domain (CID) in APC represents the threshold for pathological levels of Wnt activation and tumor transformation. Mechanistically, CID-deleted APC truncation promotes β-catenin deubiquitination through reverse binding of β-TrCP and USP7 to the destruction complex. USP7 depletion in APC-mutated CRC inhibits Wnt activation by restoring β-catenin ubiquitination, drives differentiation, and suppresses xenograft tumor growth. Finally, the Wnt-activating role of USP7 is specific to APC mutations; thus, it can be used as a tumor-specific therapeutic target for most CRCs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom